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Abstract
Background—The purpose of this study is to determine whether Ohio House Bill 341, which
mandated the use of Ohio’s Prescription Drug Monitoring Program (PDMP), was an effective
regulatory strategy to reduce opioid and benzodiazepine dispensing.
Method—Secondary analysis of Ohio’s PDMP data on prescription opioids and benzodiazepines
dispensed from November 2014 to March 2017. An interrupted time series analysis was conducted
to determine if there was a significant change in the quantity of opioids and benzodiazepines
dispensed.
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Results—After HB341 became effective in April 2015, there was a statistically significant
decrease in the monthly quantity (number of pills) opioids and benzodiazepines dispensed in Ohio.
There was a modest increase in the mean days’ supply of opioids and no change in the mean
morphine equivalent dose.
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Conclusions—Legislation in Ohio requiring prescribers to check the PDMP was effective in
reducing the quantity of opioids and benzodiazepines dispensed.
Keywords
Prescription opioids; Policy; Benzodiazepines; Dispensing

1. Introduction
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Drug overdose deaths in the United States (U.S.) have increased every year in the past
decade, and in 2015 there were approximately 33,066 overdose deaths involving an opioid
(Rudd et al., 2016). Increasing rates of drug overdose deaths have been associated with a
parallel increase in prescription opioid sales, as well as treatment admissions for opioid use
disorders from 1999 to 2008 (CDC, 2011); however, the national quantity of prescription
opioids began to decline in 2012 (Guy et al., 2017). In the absence of the number of patients
with legitimate pain that are being appropriately treated with prescription opioids, it’s
impossible to know the true excess of prescription opioids dispensed and how that has
contributed to the misuse and diversion of these drugs. Annually, approximately 11.5 million
people misuse prescription opioids (Han et al., 2017). More than 80% of people that initiate
heroin use report that they first used prescription opioids (Jones, 2013) and 80% of people
who abuse prescription opioids initiated use from legal prescriptions (Shei et al., 2015).
Prescription Drug Monitoring Programs (PDMPs) are state-level electronic registries of
prescription drugs dispensed, with the majority of the data being reported by communitybased pharmacies for scheduled medications (Bao et al., 2016). Forty-nine states have
implemented PDMPs (Manasco et al., 2016; Finley et al., 2017). Early PDMPs (the 1990s)
were used to monitor and detect illicit distribution of schedule II medications, and while
there is some variation across states regarding the purpose of the PDMP (Katz et al., 2008);
many today are being used as a tool to monitor over-prescribing at the provider level and
doctor-shopping (obtaining a similar prescription from multiple prescribers) at the patient
level (Clark et al., 2012).

Author Manuscript

Research has evaluated the effectiveness of PDMPs as a regulatory tool to reduce the
quantity of opioid prescriptions, the quantity of opioids dispensed, the mean days’ supply of
opioids, and the mean opioid morphine milligram equivalence (MME) (Bao et al., 2016;
Rasubala et al., 2015; Finley et al., 2017; Brown et al., 2017; Brady et al., 2014; Rutkow et
al., 2015). There is mixed evidence on the effectiveness of PDMPs (Finley et al., 2017;
Griggs et al., 2015); which in part may reflect different levels of PDMP implementation
and/or utilization, variation in the opioid drugs and/or drug schedules included in the
analysis, variation in the outcomes measured (i.e., prescriptions written versus dispensed),
variations in the prescribing setting (i.e., emergency department, dentist, etc.) and different
state-level PDMP characteristics (Pew Charitable Trusts, 2016). For example, a 2001–2010
multistate comparison of prescriptions written for ambulatory pain patients found that
PDMPs were associated with a 30% reduction in schedule II opioids; however, there was no
impact on the overall number of prescriptions written for opioids (Bao et al., 2016).
Florida’s PDMP was associated with a reduction in the volume of opioids dispensed based
on a claims dataset; however, this reduction was only statistically significant for high volume
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patients/prescribers and during this period Florida also passed pill mill legislation (Rutkow
et al., 2015).
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PDMPs, once implemented, take time to become fully operational. Their utility as a tool to
detect doctor shopping relies on the timeliness of dispensing data, and they are unlikely to
have a population-level impact until the majority of prescribers are using the PDMP. For
example, Ohio passed PDMP legislation in 2006; in the early years, only approximately
25% of prescribers were using it (Burke, 2016). States also need staff and funding to identify
over-prescribing, as well as to ensure that the appropriate steps are followed to investigate
such cases. Prescriber utilization has increased with the integration of PDMPs within
electronic medical records, and many states now require daily reporting of data. It is
therefore not surprising that early PDMP studies reported mixed findings (Rutkow et al.,
2015; Islam and McRae, 2014; Ringwalt et al., 2015; Chang et al., 2016); given the varying
levels of PDMP implementation and utilization by prescribers.
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Given the significant between-state variations in PDMPs (Manasco et al., 2016), there is an
increasing amount of research investigating whether specific PDMP characteristics are
associated with positive outcomes. Seventeen states mandate PDMP enrollment and only
eight states require prescribers to review a patient’s PDMP report before prescribing
controlled substances (Manasco et al., 2016). Mandatory use of the PDMP is associated with
decreases in the quantity of opioids dispensed, the number of opioids prescriptions and
multiple provider episodes (MPEs) (Rasubala et al., 2015; Freeman et al., 2015; PDMP
Center of Excellence, 2014). There is however mixed evidence regarding whether PDMPs
reduce MME or days’ supply, both of which are associated with increased risk of nonmedical use and/or overdose (Guy et al., 2017; Paulozzi, 2012). Only one study has used
PDMP data to report on benzodiazepine dispensing patterns; however, this study did not
investigate the effect of PDMP implementation or regulations on benzodiazepine dispensing
patterns (Paulozzi et al., 2015).
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Ohio has one of the highest rates of overdose fatalities in the country and some of the
highest rates of prescription drug trafficking (Rudd et al., 2016; Winstanley et al., 2012). The
Ohio Board of Pharmacy reported that 8.2 million doses of prescription opioids were
dispensed in just Scioto County alone in 2011, which was approximately 103.6 doses for
every county resident including children (Ohio Department of Health, 2012). Legislation
creating Ohio’s PDMP, Ohio’s Automated Rx Reporting System (OARRS), was passed in
May 2005 and it became law in January 2006. OARRS is managed by the Ohio Board of
Pharmacy, and it incorporates dispensing information on Schedule II–IV drugs and one noncontrolled drug, gabapentin. There are approximately 2433 pharmacies, and 48,741
prescribers in Ohio registered to use OARRS. Ohio House Bill 341 (HB341) was first
introduced on November 7, 2013, and it was passed on June 3, 2014; with an effective date
of April 1, 2015. Rules, recommendations or guidelines previously existed to encourage
prescribers to register to use OARRS or to check OARRS prior to prescribing; HB341 was
the first legislative mandate that could be enforced. Ohio HB341 requires prescribers to
check OARRS prior to initiating a prescription for opioids or benzodiazepines and
subsequently re-checking OARRS every 90 days for patients who are continued to be
prescribed these medications. HB341 incorporated exemptions to checking OARRS when
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prescribing or personally furnishing opioids and benzodiazepines when these drugs were for
less than a seven-day supply, for hospice patients, for patients with a terminal illness or with
cancer, and for patients prescribed opioids post-surgical procedures. Opioids and
benzodiazepines administered in a hospital, nursing home or residential care facility were
also exempt. Given that regulations may not have an optimal impact unless enforced, the
Ohio Board of Pharmacy identified prescribers that were not in compliance with HB341. In
August 2016, the Board mailed letters to prescribers that failed to check OARRS before
prescribing an opioid or benzodiazepine, informing them they could be fined up to $20,000.

Author Manuscript

The goal of this project was to evaluate whether the effective date of House Bill 341 was
associated with a reduction in the overall quantity of opioids and benzodiazepines dispensed
in Ohio. The secondary goals were to evaluate whether HB341 was associated with a
reduction in the days’ supply of opioids or benzodiazepines, the mean MME per opioid
prescription, and the number of multiple-provider episodes (MPE). Additionally, we
investigated whether the HB341 enforcement letters further reduced the quantity of opioids
and benzodiazepines dispensed. This study is unique from previous research as it includes
all scheduled opioids indicated for pain and it accounts for opioid schedule changes in
modeling the impact of PDMP regulations. Further, this is the first study to assess the impact
of a PDMP on benzodiazepine prescribing practices.

2. Method
2.1. Data

Author Manuscript

A reduced dataset was provided by the Ohio Board of Pharmacy, including all records of
reported dispensed medications from 2007 through the first quarter of 2017 (March 31,
2017). The dataset included information on the date filled, prescription number, prescription
refill number, quantity dispensed, days’ supply, national drug code, drug name, number of
authorized refills, payment type, pharmacy business activity code, three-digit pharmacy zip
code, patient age, patient sex, patient county, three-digit patient zip code, three-digit
prescriber zip code, and prescriber specialty. The dataset included a de-identified unique
code for patients, prescribers, and pharmacies.
2.2. Study population and sample

Author Manuscript

We restricted the data based on whom the bill targeted and was anticipated to benefit. Given
that HB341 is only applicable to prescribers licensed in Ohio, we excluded records with an
out-of-state prescriber, and only included patients who were Ohio residents. For this study,
the dataset was restricted to medications dispensed between November 1, 2014, and March
31, 2017 (n = 52, 603,348). November 1, 2014, to March 31, 2015, was defined as the preintervention period, and April 1, 2015, to March 31, 2017, was the post-intervention period.
The pre-intervention period was restricted to records after November 1, 2014, because of
prior DEA opioid re-scheduling, which is known to have influenced opioid dispensing
patterns. In August 2014, tramadol was reclassified from an unscheduled to a schedule IV
drug, and in October 2014, hydrocodone was reclassified from a schedule III to schedule II
drugs. Between 2007 to March 2016, hydrocodone represented 41.4% and tramadol
represented 17.0% of all opioids dispensed in Ohio. Therefore, including opioid dispensing
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data prior to November 2014, would violate the assumptions of interrupted time series
analysis. We developed code to classify opioids as either for the treatment of pain or
addiction. The buprenorphine transdermal patch (Butrans), solution for injection, and film
(Belbuca) were not categorized as medication-assisted treatment (MAT) because these
formulations are indicated in the treatment of pain. Methadone solution was classified as
MAT per Ohio regulations. Finally, methadone tablets were not categorized as MAT as they
are indicated in the treatment of pain.

Author Manuscript

Ohio’s PDMP data is entered by pharmacists as part of routine practice and hence data entry
errors may occur. We developed a strategy to address data entry errors and had the strategy
reviewed by the Ohio Board of Pharmacy to ensure accuracy. The first step was to remove
values that were non-permissible and the second step was to remove values that were
determined to be data entry errors. A statistical cut point of the top 0.01% was used to
identify values that were highly unlikely to be observed; a similar approach has been used
else-where (Weiner et al., 2018). For example, all ages greater than 116 years old (0.01%)
were coded as missing. This process was used for all applicable variables in the dataset.
2.3. Measures

Author Manuscript

The primary outcome variable was the quantity of opioids and benzodiazepines dispensed
per month and this included only solid doses. Solid doses included tablets, capsules, film,
suppositories, and lozenges. All other forms were categorized as non-solid. Quantity was
restricted to solid doses because in these cases “days’ supply” represents a quantifiable unit
and frequently non-solid formulations cannot be transformed into a similar unit. For opioids,
quantity only included drugs with an indication for pain. The secondary outcomes were
days’ supply of opioids and benzodiazepines, mean MME per opioid prescription, and the
number of multiple provider episodes (MPE). The MME per prescription was calculated per
prescription for only solid dose opioids and was determined from the following calculation:
(Quantity/Day Supply) × Strength × Conversion Factor. The conversion factors utilized were
from the Center Opioid Morphine Equivalent Conversion Factor chart. The Prescription
Behavior Surveillance System measure of MPE was used; which defines MPE as a patient
that fills prescriptions from five or more prescribers at five or more pharmacies within a sixmonth period (Paulozzi et al., 2015). We calculated the MPE for benzodiazepines alone,
opioids alone, and for benzodiazepines or opioids for six months’ intervals in 2015–2016.
Given that this definition of MPE is based on six-month intervals, rather than monthly, we
were not able to assess the specific impact of the passage of HB341 in April 2015. Rather,
we report the MPE trend during this period.
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2.4. Analysis
Stata SE 14.2 (StataCorp, 2013) was the statistical software package used to conduct the
analysis. Descriptive statistics were used to summarize the quantity, days’ supply and mean
MME. An interrupted time series analysis (ITSA) was used to determine whether there were
statistically significant changes in the primary and secondary outcomes between November
2014 to March 2017. A Cumby-Huizinga test (actest) suggested that there was not
autocorrelation, hence a Newey-West model was used. For the primary outcomes quantity of
opioids and benzodiazepines dispensed, we considered two models and the first included
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only the effective date of HB341 (April 2015) (Model 1). The second model included the
HB341 effective date and the enforcement letter date (August 2016) (Model 2). This
research was reviewed by the West Virginia University Institutional Review Board (IRB) and
determined not to be human subjects research.

3. Results

Author Manuscript

Between November 2014 and March 2017, there were 50.6 million prescriptions for 5.5
million unique individuals from 54,272 unique prescribers. The mean age of patients was
46.5 years old and 55.4% were female. Approximately 80% of the records were for new
prescriptions and the mean days’ supply was 23.0 (SD = 16.0). The majority (66%) of the
prescriptions were paid for with commercial insurance, 24.8% were paid for by Medicaid or
Medicare and 7.2% were paid for with cash. Over half (51.6%) of the prescriptions were for
opioids, 21.9% were for benzodiazepines and 13.3% for stimulants. Opioids included:
Hydrocodone (31.5%), Oxycodone (29.6%), Tramadol (16.8%), buprenorphine (7.1%),
Codeine (6.6%), Morphine (3.1%) and other (8.4%).
3.1. Quantity of opioids and benzodiazepines

Author Manuscript

Between November 2014 and March 2017, there were 4.7 million fewer opioids dispensed
and 1.6 million fewer benzodiazepines dispensed. The absolute quantity of opioids
dispensed decreased by 8.9% and benzodiazepines decreased by 7.5%. In model 1, there was
a statistically significant reduction (coef. = −579,000) in the quantity of opioids dispensed
after HB341 went into effect (p < 0.000) (see Fig. 1, Panel A). In model 2, there was not an
additional reduction in the quantity of opioids dispensed attributable to the enforcement
letter. However, in the period following the enforcement letter there was a statistically
significant increase in quantity of opioids dispensed (coef. = 753,061; p = 0.04) (see Fig. 1,
Panel B). Similarly, there was a statistically significant decrease (coef. = 189,000; p < 0.000)
in benzodiazepine dispensing after the passage of HB341 (see Fig. 1, Panel C) and no
change after the enforcement letters were sent (see Fig. 1, Panel D).
3.2. Days’ supply and MME
The overall mean days’ supply of solid opioids for pain was 17.6 (SD = 13.5) and 27.5 (SD
= 16.2) for benzodiazepines. There was a slight, but statistically significant, increase (coef. =
0.058; p < 0.000) in the mean days’ supply of opioids after the passage of HB341 (see Fig.
2, Panel A) and a similar pattern was observed for benzodiazepines (coef. = 0.014; p < 0.01)
(see Fig. 2, Panel A). There was no change in the mean MME (p = 0.200) (see Fig. 2, Panel
C).
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3.3. MPE
There was a statistically significant decline in MPE episodes between 2015 to 2016 for
benzodiazepines (45%), opioids (63%) and opioids or benzodiazepines (61%) (see Fig. 3).
The absolute decrease in MPE episodes was 3,067 for opioids and 8,892 for opioids or
benzodiazepines.
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4. Discussion
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After HB341 became effective, there were 4.49 million fewer opioids and 1.68 million fewer
benzodiazepines dispensed per month. The mean quantity of opioid dispensed decreased by
8.1%. This finding is consistent with the national study of Dowell et al. (2016) which
estimated that mandated PDMP review, combined with pain clinic legislation, was
associated with an 8% decrease in the quantity of opioids dispensed (Dowell et al., 2016).
Ohio passed pill mill legislation (House Bill 93) in 2011, four years prior to mandating
physicians to check a patient’s PDMP report before prescribing an opioid or benzodiazepine.
Bao et al. (2016) reported that PDMPs were associated with a statistically significant decline
in schedule II opioid prescriptions, but not for all opioid prescriptions (Bao et al., 2016).
However, the previous study focused on opioid prescriptions in the ambulatory setting rather
than all opioids dispensed. Both of these studies assessed periods prior to 2013 and may not
have accounted for the level of PDMP utilization or implementation. As PDMPs have
matured and likely improved since their initial implementation, researchers will be able to
better determine whether the initial mixed findings reflected sub-optimal prescriber
utilization or specific PDMP characteristics.
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HB341 was also effective in reducing the quantity of benzodiazepines dispensed in Ohio.
Substance use disorders and overdose deaths rarely involve just opioids. Drug users
frequently engage in poly-substance abuse, and the combination of opioids with
benzodiazepines significantly increases the risk of an overdose fatality (Sun et al., 2017).
Our study is the first study to report on how a PDMP may influence benzodiazepine
prescribing, and it is interesting to note that there were parallel reductions in
benzodiazepines and opioids dispensed. Additional research is needed to determine whether
mandatory PDMP legislation should specify checking for individual drug classes or whether
it should include all drugs tracked in the state PDMP. It seems possible that as checking a
patient’s PDMP report becomes part of routine prescribing practice for controlled
medications, that reductions in quantity or MPEs would decrease for all medications
reported to a PDMP.
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The greatest reduction in MPE was for opioids alone and while there were very few MPEs
for benzodiazepines, there was still a statistically significant decline in episodes during the
time period. Given the definition of MPE that we used, it is unknown whether the reduction
in MPEs is attributable specifically to HB341. There was a slight statistically increase in the
days’ supply for both opioids and benzodiazepines after the passage of HB341. During the
study period, the mean days’ supply of opioids ranged from 16.9 (November 2014) to 18.3
(October 2016), and benzodiazepines ranged from 27.1 (July 2015) to 27.8 (December
2016). While this increase may not be clinically significant, it may warrant longer-term
monitoring. Previous research has not found an association between PDMPs and reductions
in MME (Brady et al., 2014); nevertheless, it is important to monitor increasing MME as it
could circumvent reduction in the number of opioids dispensed. It is also important to keep
in mind that this MME calculation was per prescription and therefore does not reflect an
individual’s daily MME, which would account for overlapping prescriptions. While OARRS
will report daily MME in the screen view for prescribers, this information is not stored and
hence difficult to reconstruct. There are several other PDMP characteristics that likely

Drug Alcohol Depend. Author manuscript; available in PMC 2019 May 21.

Winstanley et al.

Page 8

Author Manuscript

influence their effectiveness, and full realization of these benefits may require prescribers to
check routinely the PDMP before prescribing. However, professional associations such as
the American College of Emergency Physicians have released policy statements that PDMPs
should be voluntary (American College of Emergency Physicians, 2017). Further, it is
unknown to what extent a PDMP’s annual budget and funding may determine its
effectiveness. PDMP’s annual costs are estimated to range between $125,000 to 1 million
(Finklea et al., 2014). In 2016, Ohio spent $4,232,963 on their PDMP to support the
operation of the system; as well as efforts to integrate OARRS directly into electronic health
records and pharmacy dispensing systems. These enhancements provide instant access to
healthcare providers, and they were implemented to encourage checking the system
regularly. It is unknown whether this level of financial investment is needed to observe
population-level improvement.

Author Manuscript

4.1. Study limitations
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Over the past decade, Ohio has implemented several strategies to address the opioid
epidemic including opioid prescribing guidelines for emergency departments and
recommendations to limit opioid prescriptions greater than 80 MME. By limiting the preintervention period to after November 2014, we attempted to control for opioid schedule
changes and these other earlier state policies that may have influenced opioid prescribing
practices. In fact, reports from the Ohio Board of Pharmacy suggest that there have been
consistent declines in opioid dispensed since OARRS was implemented in 2006. HB341
required checking a patients’ PDMP report before writing a new prescription for an opioid
or benzodiazepine, and it is unknown whether a greater effect would have been found for
patients newly prescribed such medications. It would seem reasonable that prescribers would
be less concerned about checking the PDMP for patients with whom they already have a
regular relationship. Finally, our analyses included only one state and its unknown the extent
to which the results would generalize to other states.

5. Conclusion

Author Manuscript

In conclusion, regulations mandating checking of the PDMP were effective in reducing the
quantity of opioids and benzodiazepines dispensed in Ohio. Enforcement of such regulations
may be important; however, it does not appear to reduce further the quantity dispensed. The
United States President’s Commission on Combating Drug Addiction and the Opioid Crisis’
final draft report was released in November 2017, and it recommends that federal agencies
mandate PDMP checking; however, it did not specify when PDMPs should be checked or by
whom. This research contributes to the empirical evidence that mandatory PDMP checking
for opioids and benzodiazepines is an effective regulatory strategy and additional research is
needed to determine whether these reductions, in turn, are associated with less harm
including non-medical use of prescription opioids and addiction.
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Fig. 1.
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Panel A: Monthly Quantity of Opioids Dispensed and HB341 Effective Date. Panel B:
Monthly Quantity of Opioids Dispensed, HB341 Effective Date and Enforcement Letter
Date. Panel C: Monthly Quantity of Benzodiazepines Dispensed and HB341 Effective Date.
Panel D: Monthly Quantity of Benzodiazepines Dispensed, HB341 Effective Date and
Enforcement Letter Date.
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Fig. 2.

Panel A: Mean Day’s Supply of Opioids and HB341 Effective Date. Panel B: Mean Day’s
Supply of Benzodiazepines and HB341 Effective Date. Panel C: Mean MME per opioid
prescription and HB341 Effective Date.
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Fig. 3.

Multiple Provider Episodes from 2015 to 2016 for Opioids and Benzodiazepines.
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